Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association - 1 Jun 2008

Bain Vincent G, Kaita Kelly D, Marotta Paul, Yoshida Eric M, Swain Mark G, Bailey Robert J, Patel Keyur, Cronin Patrick W, Pulkstenis Erik, McHutchison John G, Subramanian G Mani

Abstract excerpt

BACKGROUND & AIMS: A phase 2, randomized, multicenter, open-label study evaluated the safety and efficacy of albinterferon alfa-2b in interferon-alpha treatment-naïve patients with genotype 2/3, chronic hepatitis C virus infection. METHODS: Forty-three patients were randomly assigned in a 1:1 ratio to receive subcutaneous albinterferon alfa-2b 1500 microg every 4 weeks (q4wk) or every 2 weeks (q2wk) with oral...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Injections, Subcutaneous

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Ribavirin

Share to Viral Load

Source

Identifiers

PMID: 18467185
DOI: 10.1016/j.cgh.2008.02.056

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients.PMID 18467185Read ↗

Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.Semantic proximity Read ↗

Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3.Semantic proximity Read ↗

Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C.Semantic proximity Read ↗

Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C.Semantic proximity Read ↗

Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3.Semantic proximity Read ↗

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.Semantic proximity Read ↗

Association between insulin resistance and sustained virologic response in hepatitis C treatment, genotypes 1 versus 2 and 3: systematic literature review and meta-analysis.Semantic proximity Read ↗

DOES INSULIN RESISTANCE IMPAIR THE VIROLOGICAL RESPONSE TO PEGINTERFERON/RIBAVIRIN IN CHRONIC HEPATITIS C GENOTYPE 3 PATIENTS?Semantic proximity Read ↗

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.Semantic proximity Read ↗

Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C.Semantic proximity Read ↗

Population pharmacokinetics and exposure-response of albinterferon alfa-2b.Semantic proximity Read ↗

A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.